Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection.
Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to viral structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.
Wands
J R
JR
Molecular Hepatology Laboratory, Massachusetts General Hospital Cancer Center, Charlestown, USA. wands@helix.mgh.harvard.edu
Geissler
M
M
Putlitz
J Z
JZ
Blum
H
H
von Weizsäcker
F
F
Mohr
L
L
Yoon
S K
SK
Melegari
M
M
Scaglioni
P P
PP
D000998:Antiviral Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D015316:Genetic Therapy; D006509:Hepatitis B / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007114:Immunization / Q000379:methods; D009696:Nucleic Acids / Q000627:therapeutic use*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D016337:RNA, Catalytic / Q000627:therapeutic use
D000998:Antiviral Agents; D009696:Nucleic Acids; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic